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Despite several efforts in the last decades, an efficacious HIV-1 vaccine is still not avail-
able. Different approaches have been evaluated, such as recombinant proteins, viral 
vectors, DNA vaccines, and, most recently, dendritic cell (DC) targeting. This strategy 
is based on DC features that place them as central for induction of immunity. Targeting 
is accomplished by the use of chimeric monoclonal antibodies directed to DC surface 
receptors fused to the antigen of interest. In this work, we targeted eight promiscuous 
HIV-derived CD4+ T cell epitopes (HIVBr8) to the DEC205+ DCs by fusing the multiepitope 
immunogen to the heavy chain of αDEC205 (αDECHIVBr8), in the presence of the TLR3 
agonist poly (I:C). In addition, we tested a DNA vaccine encoding the same epitopes 
using homologous or heterologous prime-boost regimens. Our results showed that 
mice immunized with αDECHIVBr8 presented higher CD4+ and CD8+ T cell responses 
when compared to mice that received the DNA vaccine (pVAXHIVBr8). In addition, 
pVAXHIVBr8 priming followed by αDECHIVBr8 boosting induced higher polyfunctional 
proliferative and cytokine-producing T cell responses to HIV-1 peptides than homologous 
DNA immunization or heterologous αDEC prime/DNA boost. Based on these results, 
we conclude that homologous prime-boost and heterologous boosting immunization 
strategies targeting CD4+ epitopes to DCs are effective to improve HIV-specific cellular 
immune responses when compared to standalone DNA immunization. Moreover, our 
results indicate that antigen targeting to DC is an efficient strategy to boost immunity 
against a multiepitope immunogen, especially in the context of DNA vaccination.
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inTrODUcTiOn
Since HIV was discovered in the 1980s, there has been a remarkable progress in the treatment for 
AIDS. Despite impressive advances in the scientific knowledge and numerous trials, a safe and effec-
tive preventive HIV vaccine is still not available. The majority of licensed vaccines provide protec-
tion against other pathogens by the induction of neutralizing antibodies (nAbs), but strategies that 
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focused on the development of an effective humoral immunity 
for HIV have failed so far. The RV144 trial was the only to dem-
onstrate some level of efficacy (~31.2%) against HIV infection by 
inducing env-specific CD4+ T cells as well as antibodies that were 
able to bind to HIV, but not to neutralize it (1, 2). Moreover, the 
tested vaccine regimen induced proliferating CD4+ T cells with a 
cytotoxic profile (3). A T cell vaccine able to elicit potent cellular 
immune responses showed marked protection against simian 
immunodeficiency (SIV) challenge in non-human primates (4). 
Janes et al. (5) showed that Gag-specific T cells induced by the 
Merck Ad5Gag–nef–pol vaccine were associated with reduced 
viremia after HIV-1 infection.
The role of CD4+ T cells to support immunity places them 
as key for viral clearance, ensuring homeostasis. The important 
role of CD4 T cell responses during HIV (6) and non-human 
primate SIV infection is now clear (7). They can provide help for 
CD8+ cytotoxic T cells to control virus replication (8), especially 
in the mucosal region (9). In addition, HIV-specific CD4+ T cell 
responses promote B cell differentiation leading to generation 
or maintenance of nAbs in natural infection (10). Furthermore, 
HIV-specific CD4+ T cells can control viral replication by direct 
cytotoxicity (11) or indirectly through the secretion of soluble 
antiviral mediators (CCL3, CCL4, and CCL5) (12). A polyfunc-
tional Gag-specific CD4+ T cell response was inversely correlated 
with virus load and directly with the HIV-specific CD8+ T cell 
response in HIV-infected long-term non-progressor individuals 
(13). Furthermore, expression of specific HLA class II alleles 
has a considerable impact on the control of HIV replication. 
HLA-DRB1*15:02 is significantly associated with HIV control 
(14) and elite controllers that express HLA-DRB1*13 and HLA-
DQB1*06 class II HLA molecule showed superior mucosal Gag-
specific CD4+ T cell responses that produced simultaneously 
IFNγ, TNFα, and IL-2 when compared to non-controllers or 
individuals in highly active antiretroviral therapy (HAART) (9). 
Thus, it is now accepted that an effective vaccine should also 
promote broad and polyfunctional CD4+ T responses against 
HIV infection (15).
The inclusion of appropriate HIV-1 epitopes recognized by 
CD4+ T cells may thus play an essential role in the induction 
of immune responses to a HIV vaccine candidate. Our group 
has previously described a set of conserved HIV-1 CD4+ T cell 
epitopes from the whole proteome of the HIV-1 B subtype 
consensus that promiscuously bound to multiple HLA-DR, -DQ, 
and -DP molecules. Peripheral blood mononuclear cells from 
90% of HIV-seropositive individuals recognized these epitopes, 
and the strongest responses were found among long-term 
non-progressors (16). Epitope-based vaccines focus responses 
on epitopes with desirable properties and prevent responses to 
neutral or deleterious epitopes (17). A DNA vaccine encoding 
the mentioned conserved epitopes (HIVBr18) induced broad 
specific CD4+ and CD8+ T responses in transgenic mice express-
ing human HLA class II alleles (HLA-DR2, -DR4, -DQ6, and 
-DQ8) (18). Furthermore, HIVBr18 promoted high magnitude, 
broad, and polyfunctional CD4+ and CD8+ T cell responses 
to 8 out of 18 vaccine-encoded peptides in BALB/c mice (19). 
This epitope-based vaccine concept may cope with HIV genetic 
variability, since it induces a broad T cell response focused on 
conserved HIV epitopes, and may also provide increased popula-
tion coverage, given the promiscuity of HLA class II binding to 
multiple epitopes.
DNA vaccines are relatively easy and cheap to produce, being 
promising agents to control epidemics in remote, resource-poor 
locations (20). However, DNA vaccines have shown limited 
immunogenicity in non-human primates and in humans, pos-
sibly due to the low amount of the expressed antigen (21). For 
this reason, different approaches have been pursued in order 
to overcome this hurdle (22). Dendritic cells (DCs) have the 
ability to link innate and adaptive immunity because they are 
able to effectively acquire, process, and present a myriad of 
pathogen-derived epitopes mainly to T cells (23). In mouse 
spleen and lymph nodes, two major subtypes of resident DCs 
have been described: the CD11c+CD8α+ DCs that addition-
ally express high levels of DEC205 endocytic receptor and the 
CD11c+CD8α− that express the DCIR2 receptor (24, 25). In vivo 
antigen targeting to the CD11c+CD8α+ DCs was first demon-
strated when two model antigens were fused to a monoclonal 
antibody (mAb) directed to the DEC205+ receptor. Ovalbumin 
and hen egg lysozyme were successfully coupled to the αDEC205 
mAb, and effective presentation to either CD4+ or CD8+ T 
cells was observed, eliciting both robust humoral and cellular 
responses (26, 27). Different pathogen-derived antigens were 
shown to be efficiently processed and presented to T cells when 
targeted to the CD11c+CD8α+ DCs through αDEC205 mAb, 
such as Plasmodium yoelii (28), Plasmodium falciparum (29), 
Trypanosoma cruzi (30), Mycobacterium tuberculosis (31), HIV 
(32–34), and dengue virus (35). Furthermore, it was shown that 
targeting of HIV antigens using αDEC205 mAb could be an effi-
cient vaccine platform. A single dose of αDEC205-Gag mAb in 
the presence of poly (I:C) induced protective CD4+ T responses 
when mice were challenged with recombinant vaccinia virus 
expressing Gag (33). In addition, αDEC205-p24 in the presence 
of poly (I:C) led to strong polyfunctional CD4+ profile that was 
able to induce proliferating and cytokine-producing T cells 
(32). HIV p24 targeted to CD11c+CD8α+ DCs also induced Th1 
CD4+ T cells as well as cross-presentation to CD8+ T cells (36). 
Immunization with an anti-human DEC205-p24 mAb induced 
IFNγ- and IL-2-producing cells and was able to elicit high titers 
of anti-human IgG in transgenic mice (37). αDEC205-Gag 
targeting was also shown to assist a protective response to a 
DNA vaccine by mobilizing CD8+ T cells after challenge (38). 
More recently, αDEC205-p24 mAb was evaluated for intranasal 
immunization, and it was able to induce HIV-specific immunity 
in the gastrointestinal tract (34).
In recent years, evidence has shown that heterologous prime-
boost vaccination was an effective strategy to generate powerful 
antibody responses (39, 40), to improve the magnitude and qual-
ity of T cell responses (41), and to induce protection against dif-
ferent pathogens (42), including HIV. We thus hypothesized that 
targeting HIV CD4+ T cell epitopes to DCs using the αDEC205 
mAb would be able to induce higher specific cellular responses 
against HIV-1 when compared to a DNA vaccine encoding the 
same epitopes. In the current study, we assessed the polyfunction-
ality of HIV-specific T cell responses induced by αDECHIVBr8 
chimeric mAb and the DNA vaccine HIVBr8 in homologous and 
TaBle 1 | amino acid sequence of hiV epitopes.
epitope sequence
p6 (32–46) DKELYPLASLRSLFG
p17 (73–89) EELRSLYNTVATLYCVH
pol (785–799) GKIILVAVHVASGYI
gp160 (188–201) NTSYRLISCNTSVI
rev (11–27) ELLKTVRLIKFLYQSNP
vpr3 (65–82) QQLLFIHFRIGCRHSRIG
vif (144–158) SLQYLALVALVAPKK
nef (180–194) VLEWRFDSRLAFHHV
The sequences of HIV-1 epitopes selected for this study were previously described by 
Fonseca et al. (16). These epitopes were derived from the previously described DNA 
vaccine HIVBr18 (18, 19) and comprise the eight mentioned epitopes (HIVBr8) that can 
bind to I-Ad and are recognized by T cells from immunized BALB/c mice.
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heterologous prime-boost immunization regimens. Our results 
showed that immunization with αDECHIVBr8 solely or heter-
ologous prime-boost with HIVBr8 followed by αDECHIVBr8 
was able to induce broader and polyfunctional CD4+ and CD8+ 
T cells when compared to the DNA vaccine alone.
MaTerials anD MeThODs
epitopes
The sequences of HIV-1 epitopes selected for this study were 
previously described by Fonseca et al. (16) and are the following: 
p6 (32–46), p17 (73–89), pol (785–799), gp160 (188–201), rev 
(11–27), vpr (65–82), vif (144–158), and nef (180–194) (Table 1). 
These epitopes were derived from the previously described DNA 
vaccine HIVBr18 (18, 19) and comprise the eight mentioned 
epitopes (HIVBr8) that can bind to I-Ad and are recognized by T 
cells from immunized BALB/c mice. The epitopes were assembled 
in tandem and are separated by GPGPG at C and N termini to 
avoid the creation of junctional epitopes that may interfere with 
processing and presentation (43).
cloning the Dna sequence encoding 
hiV-1 epitopes: pVaXhiVBr8 generation
The HIVBr8 nucleotide sequence was codon optimized, and a 
Kozak sequence was included at the 5′ end to improve mam-
malian expression. The artificial gene (Genscript) was cloned 
between the HindIII and XhoI restriction sites of the pVAX1 
vector (Invitrogen) to generate the pVAXHIVBr8 plasmid that 
was amplified using DH5α cells. The pVAXHIVBr8 was purified 
using the Endofree Plasmid Giga Kit (Qiagen) according to the 
manufacturer’s instructions. The yield and quality of purified 
DNA was determined by spectrophotometry at 260  nm and 
confirmed by agarose gel electrophoresis.
Fusion of hiV-Derived cD4+ T cell 
epitopes to the αDec205 antibody: 
αDechiVBr8 mab generation
Plasmids encoding the light and heavy chains of the mouse 
αDEC205 antibody were kindly provided by Dr. Michel C. 
Nussenzweig (The Rockefeller University). The artificial HIVBr8 
gene was produced (Genscript), digested from pUC57 vector, and 
cloned in frame with the carboxyl terminus of the heavy chain of 
the mouse DEC205 (clone NLDC145) between the 5′ XhoI and 
3′ NotI sites. Large-scale preparation of plasmids pDECHIVBr8, 
empty pDEC (a negative non-fused control), and pDEC kappa 
(encoding the αDEC205 kappa light chain) were prepared using 
Maxi Plasmid Purification Kit (Qiagen), according to the manu-
facturer’s instructions. The yield and quality of purified DNA 
were determined by spectrophotometry at 260 nm and confirmed 
by agarose gel electrophoresis.
expression and Purification  
of αDechiVBr8 mab
The chimeric αDEC and αDECHIVBr8 mAbs were produced and 
purified after transfection of human embryonic kidney 293T cells 
(ATCC, CRL-11268) exactly as described (35).
immunoblot
Approximately 1  µg of the αDEC and αDECHIVBr8 mAbs 
were run on 12% SDS-PAGE gels under reducing conditions, 
and subsequently transferred to nitrocellulose membranes (GE 
Healthcare) at 100 V for 90 min in transfer buffer (glycine 39 mM, 
Tris 48 mM, SDS 10% and methanol 20%, pH 8.3). After transfer, 
nitrocellulose membranes were blocked in PBS 0.02% Tween-
20 (PBST), 5% non-fat milk, and 2.5% BSA, overnight at 4°C. 
Membranes containing the reduced mAbs were then incubated 
with peroxidase-labeled goat anti-mouse IgG Fc specific (1:5,000, 
Jackson Laboratories) plus peroxidase-labeled goat anti-mouse 
IgG kappa (1:3,000, SouthernBiotech) for 60  min at room 
temperature. After three washes with PBST, the reaction was 
developed using chemiluminescence (ECL kit, GE Healthcare) 
and captured on Kodak film.
Binding assay
Binding assays were performed using CHO cells expressing either 
the mouse DEC205 (CHOmDEC) or DCIR2 (CHOmDCIR2) 
receptors, kindly provided by Dr. Michel Nussenzweig (The 
Rockefeller University). Purified mAbs were diluted to 4, 2, or 
1 µg/mL and incubated with the CHOmDEC or CHOmDCIR2 
cells at 4°C for 30 min, exactly as described by Henriques et al. 
(35). Next, the cells were washed and incubated with anti-mouse 
IgG1-PE (clone A85-1, BD Biosciences) for 30  min at 4°C. 
Additionally, 4, 2, or 1 µg/mL of αDEC or αDECHIVBr8 mAbs 
were incubated with 5 million splenocytes at 4°C for 40  min 
and then incubated with anti-CD49b-biotin (clone DX5), 
anti-CD19-biotin (clone 1D3), anti-CD3-biotin (clone 145-
2C11), Streptavidin-APCCy7, anti-CD11c-APC (HL3), anti-
IAIE-FITC (clone 2G9), anti-CD8-Pacific Blue (clone 53-6.7), 
and anti-IgG1-PE (clone A85-1). All monoclonal antibodies 
were purchased from BD Biosciences. Fifty thousand events 
were acquired for the analysis of binding to CHO cells and 3 
million for the analysis of binding to splenocytes. Samples were 
acquired using FACS Canto II flow cytometer (BD Biosciences) 
and analyzed using the FlowJo software (version 9.9, Tree Star, 
San Carlos, CA, USA).
4Apostólico et al. HIV Vaccine Targeting to DCs
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animals and immunization
The 6- to 8-week-old female BALB/c (H-2d) mice were purchased 
from Centro de Desenvolvimento de Modelos Experimentais 
para Medicina e Biologia (CEDEME), Brazil. Groups of six 
animals were immunized with two doses—2  weeks apart—of 
4  µg of αDECHIVBr8 mAb in the presence of 50  µg of adju-
vant poly (I:C) (Invivogen) delivered intraperitoneally (IP) or 
subcutaneously (SC), or with two doses of 100 µg of the DNA 
vaccine pVAXHIVBr8 by intramuscular route (IM). The control 
groups were immunized with 4 µg of αDEC in the presence of 
50 µg of poly (I:C) or with pVAX (empty vector). Furthermore, 
for heterologous prime-boost regimen, other groups received 
one dose of the mAb followed by one dose of DNA vaccine or 
vice versa. The control groups were immunized with one dose of 
αDEC mAb together with poly (I:C) followed by one dose with 
pVAX or vice versa.
spleen cell isolation for immune assays
Two weeks after the last immunization, mice were euthanized 
and spleens were removed aseptically. After obtaining single cell 
suspensions, cells were washed in 10 mL of RPMI 1640 (Gibco). 
Cells were then resuspended in R-10 [RPMI supplemented with 
10% of fetal bovine serum (Gibco)], 2 mM L glutamine (Gibco), 
10 mM Hepes (Gibco), 1 mM sodium pyruvate (Gibco), 1% v/v 
non-essential amino acids solution (Gibco), 40  µg/mL of gen-
tamicin, 20 µg/mL of peflacin, and 5 × 10−5 M 2-mercaptoethanol 
(Gibco). The viability of cells was evaluated using 0.2% Trypan 
Blue exclusion dye to discriminate between live and dead cells. 
Cell concentration was estimated with the aid of a cell counter 
(Countess, Invitrogen) and adjusted in cell culture medium.
T cell elispot assay
Splenocytes from immunized mice were obtained as previously 
described and assayed for their ability to secrete IFNγ after in vitro 
stimulation with 5 µM of individual or pooled HIV-1 peptides 
using the ELISpot assay. The ELISpot assay was performed using 
mouse IFNγ ELISpot Ready-SET-Go! (eBiosciences) according 
to the manufacturer’s instructions. Spots were counted using an 
AID ELISpot Reader System (Autoimmun Diagnostika GmbH, 
Germany). The cutoff was 15 SFU per million splenocytes.
analysis of Polyfunctional hiV-specific  
T cell responses by Multiparametric  
Flow cytometry
To analyze HIV-specific T cell expansion, proliferation, and 
cytokine production, splenocytes from immunized mice were 
labeled with carboxyfluorescein succinimidyl ester (CFSE) (19). 
In summary, freshly isolated splenocytes were resuspended 
(50  ×  106/mL) in PBS and labeled with 1.25  µM of CFSE 
(Molecular Probes) at 37°C for 10 min. The reaction was quenched 
with RPMI 1640 supplemented with 10% FBS (R10), and cells 
were washed with R10 before resuspension in RPMI 1640. Cells 
were cultured in 96-well round-bottomed plates (5 × 105/well in 
triplicates) for 5  days at 37°C and 5% CO2 with medium only 
or pooled HIV-1 peptides (5  µM). After 4  days of incubation, 
cells were restimulated in the presence of 2  µg/mL anti-CD28 
(BD Pharmingen), 5 µM of individual or pooled HIV-1 peptides 
and brefeldin A GolgiPlug™ (BD Pharmingen) for further 12 h. 
After the incubation period, cells were washed with FACS buffer 
(PBS with 0.5% BSA and 2 mM EDTA) and surface stained with 
anti-CD3 APCCy7 (clone 145-2C11), anti-CD4 PerCP (clone 
RM4-5), and anti-CD8 Pacific Blue (clone 53-6.7) monoclonal 
antibodies for 30 min at 4°C. Cells were fixed and permeabilized 
using Cytofix/Cytoperm™ kit (BD Pharmingen), according to 
the manufacturer’s instructions. After permeabilization, cells 
were washed with Perm/Wash buffer (BD Biosciences) and 
stained intracellularly with anti-IL2 PE (clone JES6-5H4), anti-
TNFα PECy7 (clone MP6-XT22), and anti-IFNγ APC (clone 
XMG1.2) monoclonal antibodies for 30  min at 4°C. Following 
staining, cells were washed twice and resuspended in FACS 
buffer. All antibodies were from BD Pharmingen. Samples were 
acquired on a FACSCanto II flow cytometer (BD Biosciences) and 
then analyzed using FlowJo software (version 9.9, Tree Star, San 
Carlos, CA, USA). To analyze cellular polyfunctionality, we used 
the Boolean gating platform (FlowJo software) to create several 
combinations of the three cytokines (IL-2, TNFα, and IFNγ) 
within the CFSElow population resulting in seven distinct patterns. 
The percentages of cytokine-producing cells were calculated by 
subtracting background values. For each experiment performed, 
unstained and all single-color controls were processed to allow 
proper compensation.
Data analysis
Statistical significance (p-values) was calculated by using a two-
way ANOVA and Bonferroni’s or one-way ANOVA and Tukey 
honest significant difference. Statistical analysis and graphical 
representation of data was performed using GraphPad Prism 
version 5.0 software.
ethics statement
Mice were housed and manipulated under SPF conditions in the 
animal care facilities of the Division of Immunology, Federal 
University of São Paulo (UNIFESP). This study was carried out in 
accordance with the recommendations of the National Institutes 
of Health Guide for the Care and Use of Laboratory Animals and 
the Brazilian National Law (11.794/2008). The protocol (number 
3226180814) was approved by the Institutional Animal Care and 
Use Committee (CEUA) of Federal University of São Paulo.
resUlTs
αDechiVBr8 mab Binds specifically  
the Dec205 receptor
In an attempt to induce a T cell response against HIV, we cloned 
eight CD4+ T cell epitopes in fusion with the heavy chain of the 
DEC205 receptor. αDECHIVBr8 and control αDEC205 mAbs 
were purified and analyzed in 12% SDS polyacrylamide gel under 
reducing conditions. Figure 1A shows an immunoblot in which 
both mAbs were transferred to a nitrocellulose membrane and 
incubated with anti-mouse total IgG and anti-mouse IgG kappa 
FigUre 1 | continued
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chain. Two bands that correspond to the heavy chain (~50 kDa) 
and to the light chain were detected. In the αDECHIVBr8 mAb 
preparation, we detected the light chain (~25  kDa) and also a 
band of ~70 kDa that corresponds to the heavy chain of αDEC205 
fused with the HIVBr8 sequence. Next, we tested whether the 
αDECHIVBr8 mAb retained its binding capacity to either 
CHO cells expressing the mouse DEC205 receptor or to the 
CD11c+CD8α+ spleen DCs. Figure 1B shows that αDECHIVBr8 
mAb was able to specifically bind to CHO cells expressing the 
mouse DEC205 receptor in a dose-dependent manner but not 
to CHO cells expressing the mouse DCIR2 receptor. The control 
αDEC205 mAb showed the same binding pattern. More interest-
ingly, the αDECHIVBr8 mAb was able bind specifically to the 
murine CD11c+CD8α+ DCs but not to the CD11c+CD8α− DCs, 
showing its specificity for DCs that express DEC205 in  vivo. 
As expected, the control αDEC205 mAb also bound to the 
CD11c+CD8α+ DCs (Figure  1C). Taken together, these results 
showed that the αDECHIVBr8 mAb was successfully produced 
and retained its capacity to bind to murine DCs expressing 
DEC205.
immunization with the αDechiVBr8 mab 
induces higher immune responses than 
the pVaXhiVBr8 Dna Vaccine
We initially evaluated the cellular immune responses against the 
pooled HIV peptides in BALB/c mice immunized with one or 
two doses of αDECHIVBr8 mAb (4 µg) in the presence of poly 
(I:C) and compared to two doses of the pVAXHIVBr8 DNA vac-
cine (100  µg) (Figure  2A). Splenocytes from mice immunized 
with two doses of the αDECHIVBr8 mAb presented a higher 
number of specific IFNγ-producing cells when compared to 
mice immunized with two doses of the DNA vaccine (about 
280 and 180  SFU/106, respectively). In addition, no significant 
difference was observed when the groups that received one or 
two doses of the αDECHIVBr8 mAb were compared (Figure 2B). 
Notably, when specific cellular proliferation was evaluated, mice 
that received two doses of αDECHIVBr8 mAb displayed higher 
frequency of specific CD4+ (12%, Figure 2C) and CD8+ (8.5%, 
Figure  2D) T cells that proliferated when compared to all the 
other groups. Significantly, these were almost twofold higher than 
the numbers found in the group receiving two doses of pVAX-
HIVBr8 (6.6% CD4+ and 4.8% specific CD8+ T cells). Control 
groups that were immunized with αDEC mAb or pVAX plasmid 
did not show specific IFNγ production or T cell proliferation. Of 
note, the number of CD4+ and CD8+ T cells that proliferated in 
mice immunized with two doses of the αDECHIVBr8 mAb was 
higher than the number detected in mice immunized with just 
one dose. These results led us to conclude that two doses are more 
effective to induce higher immune responses.
Next, we decided to address if the route of immunization 
would alter the efficacy of the αDECHIVBr8 mAb immuniza-
tion. For that purpose, mice were immunized with two doses 
of the αDEC or αDECHIVBr8 in the presence of poly (I:C) by 
intraperitoneal (IP) or subcutaneous (SC) route (Figure 3A). As 
shown in Figure  3B, IP immunization with the αDECHIVBr8 
mAb was able to induce higher IFNγ-producing cells than the SC 
immunization. Similar results were obtained when we measured 
the percentage of specific proliferating CD4+ and CD8+ T cells 
(Figures  3C,D, respectively). Control mice immunized with 
αDEC205 mAb did not show significant production of IFNγ or 
proliferation independently of the route used. We subsequently 
characterized the profile of polyfunctional T cells. Using mul-
tiparameter flow cytometry, we detected antigen-specific T cells 
(CD4+ and CD8+) based on their ability to proliferate (CFSE dilu-
tion assay) and produce the effector cytokines IFNγ, TNFα, and 
IL2 simultaneously. Boolean combinations of proliferating and 
cytokine-positive populations indicated that immunization by IP 
route was most effective to induce higher percentage CD4+ T cells 
that proliferated and produced simultaneously IFNγ/IL2/TNFα 
or IFNγ/TNFα or TNFα only (Figure 3E). Also, IP immunization 
induced a higher percentage of CD8+ T cells that proliferated and 
produced IFNγ/IL2/TNFα simultaneously when compared to 
the group immunized by SC route (Figure 3F). We can conclude 
FigUre 1 | continued
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FigUre 2 | immunization with the chimeric αDechiVBr8 monoclonal antibody induces higher immune responses when compared to immunization 
with the pVaXhiVBr8 Dna vaccine. BALB/c mice (n = 6) were immunized with one or two doses of 4 µg of αDEC or αDECHIVBr8 in the presence of poly (I:C) 
adjuvant (IP) or two doses of 100 µg of pVAX or pVAXHIVBr8 DNA vaccine (IM). (a) Immunization scheme. Fifteen days after the second dose, the spleen of each 
animal was removed and the splenocytes (B) were cultured in the presence of pooled HIV-1 peptides (5 µM) for 18 h to evaluate the number of IFN-γ-producing 
cells by ELISpot assay. SFU, spot forming units. Cutoff = 15 SFU/106 cells and is represented by the dotted line. (c,D) Splenocytes were labeled with 
carboxyfluorescein succinimidyl ester (CFSE) (1.25 µM) and cultured in the presence of pooled HIV-1 peptides (5 µM) for 5 days to evaluate specific proliferation. 
After staining with fluorochrome-labeled anti-CD3, anti-CD4, and anti-CD8 monoclonal antibodies, cells were analyzed by flow cytometry. CFSE dilution on gated 
CD3+CD4+ (c) or CD3+CD8+ (D) cells was used as readout for antigen-specific proliferation. One million events were acquired in a live lymphocyte gate. The percent 
of proliferating CD4+ and CD8+ CFSElow cells was determined in the CD3+ cell population. The percentage of proliferating T cells was calculated subtracting by the 
values of stimulated from non-stimulated cultures. NS, not significant; *p < 0.05; **p < 0.01; ***p < 0.001. Data represent mean ± SD.
FigUre 1 | continued 
The chimeric αDechiVBr8 was successfully produced and retained its ability to bind to cells expressing the Dec205 receptors. (a) One microgram of 
each monoclonal antibody (mAb) was run on 12% SDS-PAGE under reducing conditions. An immunoblot was performed using peroxidase-labeled goat anti-mouse 
IgG Fc specific and peroxidase-labeled goat anti-mouse IgG kappa. Molecular weight (kilodaltons), αDEC (control), and αDECHIVBr8; (B) CHO cells expressing 
either DEC205 (left) or DCIR2 (right) receptors were incubated with 4, 2, or 1 µg/mL of αDEC (control) or αDECHIVBr8, following staining with anti-mouse IgG1 PE 
antibody. Fifty thousand events were acquired in FACS Canto II and analysis was performed using FlowJo software; (c) 5 million splenocytes from BALB/c mice 
were incubated with 4, 2, or 1 µg/mL of the chimeric αDECHIVBr8 or αDEC mAbs. Splenocytes were then incubated with a pool of fluorescent antibodies and gated 
as singlets and CD3−CD19−CD49b−. Dendritic cells were selected as CD11c+ IAIE+ and subsequently divided into CD8α+ and CD8α−. Binding was detected on 
3 × 106 cells using an anti-mouse IgG1-PE antibody. Analysis was performed using FlowJo software.
7
Apostólico et al. HIV Vaccine Targeting to DCs
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 101
that immunization using two doses of the αDECHIVBr8 mAb 
by the IP route was better to induce T cell responses with greater 
magnitude and more polyfunctional than those induced by the 
pVAXHIVBr8 DNA vaccine encoding the same epitopes.
homologous or heterologous 
αDechiVBr8 Prime-Boost enhances  
iFn-γ Production, T cell Proliferation,  
and Polyfunctional T cells
To test whether a heterologous prime-boost strategy would work 
with chimeric mAb, groups of mice were then immunized with 
one dose of αDECHIVBr8 mAb (prime) followed by one dose of 
the pVAXHIVBr8 DNA vaccine (boost), or vice versa, and com-
pared to the homologous prime-boost immunization strategy 
(two doses of chimeric mAb or DNA vaccine) (Figure 4A). Two 
weeks after the boost, splenocytes from immunized mice were 
incubated with pooled peptides and specific IFNγ production 
was measured by ELISpot assay. We detected the highest numbers 
of IFNγ-producing cells against the pooled peptides in mice that 
received two doses of αDECHIVBr8 and in the group receiving 
pVAXHIVBr8 priming followed by αDECHIVBr8 mAb boosting 
(Figure 4B). Interestingly, mice primed with αDECHIVBr8 mAb 
and boosted with pVAXHIVBr8 showed a lower response when 
FigUre 3 | The intraperitoneal route elicits higher T cell responses in the spleen than subcutaneous administration of the chimeric αDechiVBr8 
monoclonal antibody. BALB/c mice (n = 6) were immunized with two doses of 4 µg of αDEC or αDECHIVBr8 in the presence of poly (I:C) adjuvant by 
intraperitoneal (IP) or subcutaneous (SC) routes. (a) Immunization scheme. Fifteen days after the second dose, the spleen of each animal was removed and the 
splenocytes (B) were cultured in the presence pooled HIV-1 peptides (5 µM) for 18 h to evaluate the number of IFN-γ-producing cells by ELISpot assay. SFU, spot 
forming units. Cutoff = 15 SFU/106 cells and is represented by the dotted line. (c,D) Splenocytes were labeled with carboxyfluorescein succinimidyl ester (CFSE) 
(1.25 µM) and cultured in the presence of pooled HIV-1 peptides (5 µM) for 5 days to evaluate specific proliferation. After staining with fluorochrome-labeled 
anti-CD3, anti-CD4, and anti-CD8 monoclonal antibodies, cells were analyzed by flow cytometry. CFSE dilution on gated CD3+CD4+ (c) or CD3+CD8+ (D) cells was 
used as readout for antigen-specific proliferation. For detection of cytokine-producing T cells, cells were pulsed on day 4 for 12 h with pooled peptides in the 
presence of anti-CD28 and brefeldin A. Cells were then surface stained with anti-CD3, CD4, and CD8, permeabilized, and stained for intracellular cytokines. 
Multiparameter flow cytometry was used to determine the frequency of IFNγ-, IL2-, or TNFα-producing CD4+ and CD8+ T cells (e,F). After gating on proliferating 
(CFSElow) and cytokine-producing cells, Boolean combinations were then created using FlowJo software to determine the frequency of each response based on all 
possible combinations of cytokine-producing CD4+ (e) and CD8+ (F) T cells. One million events were acquired in a live lymphocyte gate. The percentage of 
proliferating and cytokine-producing T cells was calculated subtracting the values of stimulated from non-stimulated cultures. NS, not significant; *p < 0.05; 
**p < 0.01; ***p < 0.001. Data represent mean ± SD.
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FigUre 4 | continued
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FigUre 4 | continued 
homologous αDechiVBr8 monoclonal antibody (mab) immunization or heterologous prime-boost induces polyfunctional T cell responses. BALB/c 
mice (n = 6) were immunized with two doses of 4 µg of αDECHIVBr8 in the presence of poly (I:C) adjuvant (IP) or two doses of 100 µg of pVAXHIVBr8 DNA vaccine 
(IM). For heterologous regimens, mice were immunized with one dose of αDECHIVBr8 followed by one dose of DNA vaccine or vice versa. The control groups were 
immunized with one dose of αDEC mAb together with poly (I:C) followed by one dose with pVAX or vice versa. (a) Immunization scheme. Fifteen days after the 
second dose, the spleen of each animal was removed and the splenocytes (B) were cultured in the presence of pooled HIV-1 peptides (5 µM) for 18 h to evaluate 
the number of IFN-γ-producing cells by ELISpot assay. SFU, spot forming units. Cutoff = 15 SFU/106 cells and is represented by the dotted line. (c,D) Splenocytes 
were labeled with carboxyfluorescein succinimidyl ester (CFSE) (1.25 µM) and cultured in the presence of pooled HIV-1 peptides (5 µM) for 5 days to evaluated 
specific proliferation. After staining with fluorochrome-labeled anti-CD3, anti-CD4, and anti-CD8 monoclonal antibodies, cells were analyzed by flow cytometry. CFSE 
dilution on gated CD3+CD4+ (c) or CD3+CD8+ (D) cells was used as readout for antigen-specific proliferation; For detection of cytokine-producing T cells, cells were 
pulsed on day 4 for 12 h with pooled peptides in the presence of anti-CD28 and brefeldin A. Cells were then surface stained with anti-CD3, CD4, and CD8, 
permeabilized, and stained for intracellular cytokines. Multiparameter flow cytometry was used to determine the frequency of IFNγ-, IL2-, or TNFα-producing CD4+ 
and CD8+ T cells (e,F). After gating on proliferating (CFSElow) and cytokine-producing cells, Boolean combinations were then created using FlowJo software to 
determine the frequency of each response based on all possible combinations of cytokine-producing CD4+ (e) and CD8+ (F) T cells. One million events were 
acquired in a live lymphocyte gate. The percentage of proliferating and cytokine-producing T cells was calculated subtracting the values of stimulated from 
non-stimulated cultures. NS, not significant; *p < 0.05; **p < 0.01; ***p < 0.001. Data represent mean ± SD.
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compared to the two previously described groups. Finally, mice 
immunized with two doses of pVAXHIVBr8 presented the lowest 
number of IFNγ-producing cells (416 SFU/106 cells, Figure 4B). 
A similar pattern was observed when we analyzed the percent 
of CD4+ and CD8+ specific proliferation (Figures 4C,D, respec-
tively): mice immunized with two doses of αDECHIVBr8 mAb 
displayed 8.23% of CD4+ and 7.49% of CD8+ T cell specific pro-
liferation, while pVAXHIVBr8 (prime)/αDECHIVBr8 (boost) 
displayed 7.04 and 7.86%, respectively. Lower percentages were 
observed in mice immunized with two doses of pVAXHIVBr8 
or αDECHIVBr8 mAb (prime)/pVAXHIVBr8 (boost). In 
addition, we characterized the phenotype and functionality of 
antigen-specific CD4+ and CD8+ T cells based on their ability to 
proliferate (CFSElow) and produce IFNγ, TNFα, and IL2 individu-
ally or in combinations (Figure S1 in Supplementary Material). 
Figure 4E shows once more that immunization with two doses 
of αDECHIVBr8 and pVAXHIVBr8 (prime)/αDEC205-HIVBr8 
(boost) were most effective to induce higher percentage of CD4+ 
T cells that proliferated and produced simultaneously IFNγ/
TNFα or IFNγ only or TNFα only. When we analyzed the CD8+ 
T cells, two doses of pVAXHIVBr8 DNA vaccine showed a 
higher percentage of CD8+ T cell proliferating and producing 
only IFNγ when compared to the other groups (Figure 4F). By 
contrast, CD8+ T cells from mice immunized with two doses of 
αDECHIVBr8 and pVAXHIVBr8 (prime)/αDECHIVBr8 (boost) 
were able to proliferate and mainly produce TNFα. αDEC and 
pVAX immunized mice displayed negligible percentages of 
specific proliferating/cytokine-producing T cells. Extended com-
parative analysis revealed that αDECHIVBr8 and αDECHIVBr8 
(prime)/pVAXHIVBr8 (boost) immunized mice displayed higher 
frequency of non-proliferating (CFSEhigh) IFNγ+/IL2+/TNFα+ and 
CFSEhigh IFNγ+/TNFα+-producing CD4+ T cells when compared 
to other groups (Figure S2A in Supplementary Material). Analysis 
of CD8+ T cell compartment demonstrated that αDECHIVBr8 
(prime)/pVAXHIVBr8 (boost) was the most efficient strategy 
to induce CFSEhigh IFNγ+/IL2+/TNFα+ and CFSEhigh IFNγ+ cells, 
while αDECHIVBr8 immunization induced higher frequency of 
CFSEhigh TNFα+ cells (Figure S2B in Supplementary Material). 
Taken together, these results showed that homologous immuni-
zation with αDECHIVBr8 mAb or heterologous pVAXHIVBr8 
(prime)/αDECHIVBr8 (boost) were able to induce broad specific 
cellular responses, and polyfunctional CD4+ and CD8+ T cells 
that proliferated and produced effector Th1 cytokines to epitopes 
encoded by the chimeric mAb and the DNA vaccine.
In an attempt to improve the cellular immune response induced 
by the DNA vaccination alone and compare it to the homologous 
immunization with αDECHIVBr8 or with the heterologous 
pVAXHIVBr8 (prime)/αDECHIVBr8 (boost), we decided 
to administer one additional dose of either αDECHIVBr8 or 
 pVAXHIVBr8. In this way, the homologous immunization groups 
received three doses of either αDECHIVBr8 or pVAXHIVBr8, 
while the heterologous immunization group received one dose 
of pVAXHIVBr8 followed by two boosters of αDECHIVBr8. 
Control groups received three doses of either αDEC or pVAX 
(Figure 5A). To assess the magnitude of the immune response, 
we evaluated specific IFNγ-producing cells in splenocytes from 
immunized mice stimulated with pooled peptides (Figure 5B). 
Once again, we observed no difference between animals immu-
nized with three doses of αDECHIVBr8 and animals immunized 
with pVAXHIVBr8 once/αDECHIVBr8 twice. By contrast, the 
group immunized with pVAXHIVBr8 thrice presented a lower 
number of specific IFNγ-producing cells. In addition, as observed 
with the administration of two doses, CD4+ and CD8+ T cells 
(Figures  5C,D, respectively) from mice immunized with three 
doses of αDECHIVBr8, and one dose pVAXHIVBr8 followed 
by two doses of αDECHIVBr8 displayed higher T cell prolif-
eration against the pooled HIV-1 peptides than three doses of 
pVAXHIVBr8. By contrast, mice immunized with three doses 
of pVAXHIVBr8 continued to present a lower percentage of 
proliferation when compared to the two previous groups. αDEC 
and pVAX immunized mice presented negligible numbers of 
IFNγ-producing cells and T cell proliferation. Boolean combina-
tions of proliferating and cytokine-positive populations indicated 
that homologous immunization with αDECHIVBr8 (3×) or with 
pVAXHIVBr8 (1×)/αDECHIVBr8 (2×) induced polyfunctional 
CD4+ T cells that proliferated and produced simultaneously 
IFNγ/TNFα, or IFNγ, or TNFα only (Figure 5E). Similar results 
were observed when CD8+ T cells were analyzed (Figure  5F). 
CD4+ and CD8+ T cells from mice immunized with the controls 
αDEC and pVAX displayed negligible percentages of specific 
FigUre 5 | continued
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FigUre 6 | immunization with homologous or heterologous prime-boost induces broad T cell responses. BALB/c mice (n = 6) were immunized with two 
doses of 4 µg of αDECHIVBr8 in the presence of poly (I:C) adjuvant (IP) or two doses of 100 µg of pVAXHIVBr8 DNA vaccine (IM). For heterologous regimens, mice 
were immunized with one dose of the DNA vaccine followed by one dose of monoclonal antibody. (a) Immunization scheme. Fifteen days after the last 
immunization, splenocytes were cultured (B) with individual HIV-1 peptides (5 µM) for 18 h to evaluate the number of IFN-γ-producing cells by ELISpot assay, SFU, 
spot forming units. Cutoff = 15 SFU/106 cells and is represented by the dotted line.
FigUre 5 | continued 
The chimeric αDechiVBr8 monoclonal antibody (mab) is more immunogenic even with increased doses of the Dna vaccine. BALB/c mice (n = 6) were 
immunized with three doses of 4 µg of αDECHIVBr8 in the presence of poly (I:C) adjuvant (IP) or three doses of 100 µg of pVAXHIVBr8 DNA vaccine (IM). For 
heterologous regimens, mice were immunized with one dose of DNA vaccine followed by two doses of the chimeric mAb. (a) Immunization scheme. Fifteen days 
after the second dose, the spleen of each animal was removed and the splenocytes (B) were cultured in the presence of pooled HIV-1 peptides (5 µM) for 18 h to 
evaluate the number of IFN-γ-producing cells by ELISpot assay. SFU, spot forming units. Cutoff = 15 SFU/106 cells and is represented by the dotted line. (c,D) 
Splenocytes were labeled with carboxyfluorescein succinimidyl ester (CFSE) (1.25 µM) and cultured in the presence of pooled HIV-1 peptides (5 µM) for 5 days to 
evaluate specific proliferation. After staining with fluorochrome-labeled anti-CD3, anti-CD4, and anti-CD8 monoclonal antibodies, cells were analyzed by flow 
cytometry. CFSE dilution on gated CD3+CD4+ (c) or CD3+CD8+ (D) cells was used as readout for antigen-specific proliferation. For detection of cytokine-producing 
T cells, cells were pulsed on day 4 for 12 h with pooled peptides in the presence of anti-CD28 and brefeldin A. Cells were then surface stained with anti-CD3, CD4, 
and CD8, permeabilized, and stained for intracellular cytokines. Multiparameter flow cytometry was used to determine the frequency of IFNγ-, IL2-, or TNFα-
producing CD4+ and CD8+ T cells (e,F). After gating on proliferating (CFSElow) and cytokine-producing cells, Boolean combinations were then created using FlowJo 
software to determine the frequency of each response based on all possible combinations of cytokine-producing CD4+ (e) and CD8+ (F) T cells. One million events 
were acquired in a live lymphocyte gate. The percent of proliferating CD4+ and CD8+ CFSElow cells was determined in the CD3+ cell population. The percentage of 
proliferating and cytokine-producing T cells was calculated subtracting the values of stimulated from non-stimulated cultures. NS, not significant; *p < 0.05; 
**p < 0.01; ***p < 0.001. Data represent mean ± SD.
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proliferating/cytokine-producing T cells. Taken together, these 
results indicate that an additional dose of pVAXHIVBr8 does not 
improve the magnitude of the T cell responses over immuniza-
tion with αDECHIVBr8 mAb.
immunization with chimeric αDechiVBr8 
mab induces Broad T cell responses
To evaluate whether immunization induces broad T cell 
responses, splenocytes from mice immunized with two doses of 
αDECHIVBr8 and pVAXHIVBr8 or heterologous prime-boost 
regimens (Figure  6A) were incubated with each of the eight 
individual HIV-1 peptides present in the chimeric mAb or DNA 
vaccine. We detected IFNγ-producing cells against all tested 
peptides. Immunization with two doses of αDECHIVBr8 mAb or 
with pVAXHIVBr8 (prime)/αDECHIVBr8 (boost) elicited signifi-
cantly higher numbers of IFNγ-producing cells when compared to 
mice immunized with two doses of pVAXHIVBr8 or that received 
αDECHIVBr8 (prime)/pVAXHIVBr8 (boost) (Figure 6B).
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In summary, ours results demonstrate that immunization of 
BALB/c mice with two or three doses of αDECHIVBr8 mAb 
or heterologous prime-boost with pVAXHIVBr8 followed by 
αDECHIVBr8 were able to induce specific immune responses 
with a higher number of IFNγ-producing cells, and polyfunc-
tional CD4+ and CD8+ T cells that proliferated and produced 
effector Th1 cytokines.
DiscUssiOn
In this paper, we provide the first evidence that a multiepitopic 
vaccine can be targeted to DCs via DEC205 mAb. Furthermore, 
homologous prime-boosting with the αDECHIVBr8, or het-
erologous DNA prime followed by αDECHIVBr8 boosting 
encoding the same epitopes, can induce T cell responses of higher 
magnitude, polyfunctionality, and breadth than homologous 
prime-boost with the DNA vaccine.
In a previous study, our group demonstrated that a DNA vac-
cine encoding 18 HIV-derived promiscuous and preserved CD4+ 
T cell epitopes (16) was able to induce broad CD4+ and CD8+ T 
cell responses in different strains of HLA class II transgenic mice 
(DR2, DR4, DQ6, and DQ8) (18). Furthermore, the HIVBr18 
DNA vaccine induced polyfunctional and long-lived CD4+ 
and CD8+ T cells responses to 8/18 HIV peptides encoded by 
the DNA vaccine (19). Despite promising, DNA vaccines show 
reduced immunogenicity in humans (21), and in the last decades, 
several strategies have been developed in order to increase the 
immunogenicity of these vaccines (17).
Initial attempts at developing a vaccine against HIV have 
focused mainly on the induction of humoral immune response 
against the viral gp120 protein and were not able to confer protec-
tion (44). In order to improve the induced immune response, the 
RV144 trial performed an immunization scheme that included 
a prime with a viral vector followed by a boost with Env protein 
and reported ~30% of protection in vaccinated individuals (1). 
A more detailed analysis of the immunized and protected indi-
viduals did not show CD8+ responses but CD4+ T cell responses 
to HIV correlated with reduced acquisition (2). Although the 
importance of CD8+ cytotoxic T cells as a first response against 
HIV (45, 46) is well established, a strong CD4+ T cell response is of 
utmost importance for the slow progression to AIDS (8). A recent 
study showed that untreated HIV-infected controllers presented 
higher Gag-specific CD4+ T cell responses and higher titers of 
nAbs against Env (10). Moreover, in non-human primates, deple-
tion of CD4+ T cells markedly reduced protection mediated by 
vaccination after SIV challenge (47). Hence, an effective vaccine 
against HIV should induce specific cytotoxic responses as well as 
CD4+ T cell responses.
In an attempt to improve the HIV-specific cellular response, 
we targeted eight previously recognized epitopes derived from 
the HIVBr18 DNA vaccine directly to DCs. This is accomplished 
by the use of DC receptor-specific mAbs fused to the antigen 
of interest. We produced an αDEC205 chimeric mAb contain-
ing the sequence of eight HIV-derived CD4+ T cell epitopes 
(αDECHIVBr8) (18, 19) and compared DC targeting through 
αDECHIVBr8 mAb with the DNA vaccine pVAXHIVBr8. We 
initially showed that the αDECHIVBr8 mAb was successfully 
produced and retained its ability to bind to the DEC205 recep-
tor, especially to the CD11c+CD8α+ DCs that naturally express 
the DEC205 receptor. The use of chimeric αDEC205 to deliver 
HIV antigens, especially Gag, to DCs has been previously 
reported (32, 33). Targeting Gag to CD8α+ DCs leads to a strong 
polyfunctional CD4+ (32, 37) and also CD8+ T cell responses (36) 
including in the gastrointestinal tract (34).
To address the minimum number of doses to induce specific 
immune responses, BALB/c mice were immunized with one 
or two doses of αDECHIVBr8 in the presence of poly (I:C) 
or with pVAXHIVBr8 DNA vaccine. We found that mice 
immunized with two doses of chimeric αDECHIVBr8 mAb 
developed a stronger CD4+ and CD8+ T cell response when 
compared to mice that received one dose of αDECHIVBr8 
mAb or two doses of the DNA vaccine after stimulation with 
pooled HIV-1 peptides, demonstrating the effectiveness of the 
approach in the context of a chimeric multiepitope vaccine 
antigen. Next, we determined which immunization route was 
more effective. BALB/c received two doses of αDECHIVBr8 
plus poly (I:C) by intraperitoneal (IP) or subcutaneous (SC) 
route. Although some studies have demonstrated the efficacy 
of the subcutaneous immunization with αDEC mAbs (27, 48), 
we detected a stronger CD4+ and CD8+ T cell response when 
αDECHIVBr8 was delivered IP. These results confirm what has 
already been demonstrated by other studies that used the IP 
route and showed high magnitude of specific cellular immune 
responses against different pathogens such as Yersinia pestis 
(49), Plasmodium sp. (28), papilloma virus (50), Leishmania 
major (51), Epstein–Barr virus (52), dengue virus (35), T. cruzi 
(30), and HIV (32, 33).
Some studies on the clinical course of HIV-1 have associated 
CD4+ T cells exhibiting polyfunctional profile with better control 
of disease. In elite controllers, superior polyfunctional CD4+ 
T cell response is observed when compared to non-controller 
individuals in HAART (53–55), including in the mucosal region 
(56). In RV144 trial analysis, vaccinees with polyfunctional CD4+ 
T cell responses against HIV peptides were found to have a lower 
rate of infection (57). Besides, the presence of specific HLA class 
II (DRB1*13, DQB1*06, and DRB1*15:02)-restricted CD4+ T cell 
responses (9, 14) play an important role in HIV immune control. 
In the present study, we show the induction of both polyfunc-
tional CD4+ and CD8+ T cell responses after immunization with 
αDECHIVBr8 in the presence of poly (I:C).
When antigens are targeted to the DEC205+ DC population, 
they can be presented to CD4+ (58) as well as to CD8+ T cells (48). 
Other studies showed that antigens encapsulated in nanoparticles 
and targeted to the DEC205+ DCs are presented by MHC class I 
and induce specific CD8+ T cell responses (59, 60). This phenom-
enon can be explained by the ability of the CD11c+CD8α+ DCs 
to perform cross-presentation (61). Our study demonstrates that 
targeting promiscuous HIV epitopes to CD8α+ DC induce both 
CD4+ and CD8+ T cell-mediated immunity.
In recent years, several studies have shown that heterologous 
prime-boost immunization is able to increase the magnitude 
and quality of the immune response to many pathogens, includ-
ing HIV (39). This approach started to be used in attempt to 
develop vaccines against pathogens that require more robust 
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humoral and cellular immune responses such as HIV (62), 
M. tuberculosis, and Plasmodium sp. (42). In this work, we found 
that pVAXHIVBr8 DNA vaccine priming followed by boost 
with the αDECHIVBr8 mAb boosting increased the overall 
magnitude of the responses against HIV peptides when the 
opposite was tested (priming with αDECHIVBr8 followed by 
pVAXHIVBr8 boost). Our results have shown that receiving two 
doses of αDECHIVBr8 mAb or a pVAXHIVBr8/αDECHIVBr8 
heterologous prime-boost induced a stronger CD4+ and CD8+ 
polyfunctional T cell response than any other immunization 
schemes tested. DNA vaccines have been shown to be most 
effective when administrated as a prime in vaccine formulations 
(63, 64). In our model, chimeric αDEC205 mAb was more effec-
tive as a boost exceptionally when the analysis was performed in 
non-proliferating (CFSEhigh) cytokine-producing cells. Of note, 
targeted αDEC205-Gag has been successfully used as a priming 
platform followed by recombinant vaccinia as boost to induce 
robust cellular immunity (34, 65).
In an attempt to improve the pVAXHIVBr8 magnitude, we 
immunized mice with three doses in the homologous or heterolo-
gous prime-boost regimens. We analyzed the ability of the cells 
from immunized mice to produce cytokines and proliferate at 
the same time. Overall, we observed the same phenomenon that 
occurred in animals that received only two doses showing that an 
additional dose of pVAXHIVBr8 did not increase the magnitude 
to the same level as immunization with αDECHIVBr8 (3×) or 
with pVAXHIVBr8 prime (1×)/αDECHIVBr8 (2×).
Our results have shown that immunization with two doses 
of αDECHIVBr8 mAb or with pVAXHIVBr8 followed by 
αDECHIVBr8 boost elicited higher magnitude T cell responses 
against all the peptides indicating a broad T cell response. Indeed, 
recent efficacy trials of T cell-based HIV vaccines showed that 
for protection, it is necessary to induce broad T cell responses 
toward conserved epitopes (2, 46, 66). An adenovirus-based 
SIV vaccine encoding eight virus proteins elicited broad T cell 
responses that reduced viremia after heterologous challenge (67) 
and the vaccine-induced response correlated with higher CD4+ 
T cell responses (68). Hence, vaccine candidates that expand the 
breadth of CD4+ and CD8+ T cell responses must be developed 
in order to provide optimal T-cell responses that may cope with 
the diverse circulating strains of HIV (69).
Our results provide evidence that multiepitope targeting to 
DCs can provide superior CD4+ and CD8+ T cell responses as 
compared to DNA vaccines alone. Given the known protec-
tive potential of CD4+ T responses elicited by αDEC205 mAb 
DC-targeted immunization (33), direct DC targeting, or the 
combination of DNA priming followed by DC targeting, is 
a promising platform for increasing HIV immunity after 
vaccination.
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FigUre s1 | Flow cytometer analysis of cellular proliferation and 
intracellular cytokine production. Representative dot plots of a seven-color 
flow cytometry panel used for the detection of carboxyfluorescein succinimidyl 
ester (CFSE), IFNγ-, IL2-, and TNFα-producing T cells after in vitro stimulation 
with pooled HIV peptides. After gating on proliferating (CFSElow) or non-
proliferating (CFSEhigh) and cytokine-producing cells, Boolean combinations were 
then created using FlowJo software to determine the frequency of each response 
based on all possible combinations of cytokine-producing T cells. The frequency 
of IFNγ-, IL2-, or TNFα cytokine-producing CFSElow or CFSEhigh CD4+ T cells is 
displayed.
FigUre s2 | homologous αDechiVBr8 monoclonal antibody (mab) 
immunization or heterologous prime-boost induces polyfunctional T cell 
responses. BALB/c mice (n = 6) were immunized with two doses of 4 µg of 
αDECHIVBr8 in the presence of poly (I:C) adjuvant (IP) or two doses of 100 µg of 
pVAXHIVBr8 DNA vaccine (intramuscular). For heterologous regimens, mice were 
immunized with one dose of αDECHIVBr8 followed by one dose of DNA vaccine 
or vice versa. The control groups were immunized with one dose of αDEC mAb 
together with poly (I:C) followed by one dose with pVAX or vice versa. Fifteen 
days after the second dose, the spleen of each animal was removed and the 
splenocytes were labeled with carboxyfluorescein succinimidyl ester (CFSE) 
(1.25 µM) and cultured in the presence of pooled HIV-1 peptides (5 µM) for 
5 days to evaluated specific proliferation. For detection of cytokine-producing 
T cells, cells were pulsed on day 4 for 12 h with pooled peptides in the presence 
of anti-CD28 and brefeldin A. Cells were then surface stained with anti-CD3, 
CD4, and CD8, permeabilized, and stained for intracellular cytokines. 
Multiparameter flow cytometry was used to determine the frequency of IFNγ-, 
IL2-, or TNFα-producing CD4+ and CD8+ T cells. After gating on non-proliferating 
(CFSEhigh) and cytokine-producing cells, Boolean combinations were then created 
using FlowJo software to determine the frequency of each response based on all 
possible combinations of cytokine-producing CD4+ (a) and CD8+ (B) T cells. 
One million events were acquired in a live lymphocyte gate. The percentage of 
proliferating and cytokine-producing T cells was calculated subtracting the values 
of stimulated from non-stimulated cultures. NS, not significant; *p < 0.05; 
**p < 0.01; ***p < 0.001. Data represent mean ± SD.
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